Compare Ascendis Pharma A/S (ASND) vs YieldMax AI & Tech Portfolio Option Income ETF (GPTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs YieldMax AI & Tech Portfolio Option Income ETF — how do they compare? Ascendis Pharma A/S trades at $255.67 (market cap $16.67B), while YieldMax AI & Tech Portfolio Option Income ETF trades at $43.11. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals.
| ASND | GPTY | |
|---|---|---|
Market Cap | $16.67B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $277.18 | $50.52 |
52-Week Low | $189.74 | $34.73 |
Enterprise Value | $17.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.17, down slightly by 0.18% on the day, while maintaining strong analyst support with 92% buy ratings and a $309.75 consensus price target. The company shows impressive revenue growth from $51M in 2022 to $720M in 2025, with profitability improving as net loss narrows to -$228M. Recent technical indicators show a bullish trend with the stock trading near resistance at $255-257, while fundamental metrics reveal high valuation ratios (P/E 29.05, P/S 15.68) offset by exceptional gross margins of 89.04%.
ASND presents a compelling growth story with multiple product launches in rare endocrine diseases driving revenue expansion, though investors face risks from negative shareholder equity and high debt levels. The company's transition to positive operating cash flow ($54M in 2025) and inclusion in Russell indexes signal maturation, but execution risks remain as the stock trades at premium valuations requiring continued strong performance to justify current levels.
GPTY trades at $43.11, up 1.07% with a bullish technical signal supported by moving averages. The YieldMax AI & Tech Portfolio Option Income ETF demonstrates consistent weekly dividend distributions, with recent payouts ranging from $0.28-$0.37. Technical indicators show strong momentum with RSI at 83.06 suggesting potential overbought conditions, while support and resistance cluster around $42-$43 levels.
The ETF's strategy of harvesting options premiums from AI and semiconductor stocks provides high yield exposure, though the concentrated tech focus and elevated RSI levels warrant caution. Recent analysis highlights GPTY's balance of income generation and capital preservation compared to peers, but dependence on semiconductor momentum presents volatility risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →
